Efficacy of Ribociclib and Abemaciclib

Ribociclib and Abemaciclib are two different drugs, although they are both targeted drugs used in the treatment of breast cancer and are CDK 4/6 inhibitors. Ribociclib is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, in combination with aromatase inhibitors or fulvestrant as initial endocrine therapy, or for women who have previously received endocrine therapy. Women on secretory therapy; Abeciclib can be used together with endocrine therapy (tamoxifen) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, lymph node-positive, early-stage breast cancer with a high risk of recurrence.